Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

2.835
+0.0200.71%
Volume:5.85M
Turnover:16.17M
Market Cap:1.74B
PE:195.57
High:2.845
Open:2.825
Low:2.665
Close:2.815
52wk High:15.960
52wk Low:2.665
Shares:615.00M
HK Float Shares:615.00M
Volume Ratio:1.02
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.014
ROE:-4.11%
ROA:-1.28%
PB:0.56
PE(LYR):195.57
PS:2.39

Loading ...

Shandong Boan Biotechnology's Cancer Drug Candidate Gets IND Acceptance; Shares Down 5%

MT Newswires Live
·
Jul 08

BOAN BIOTECH’s BA1203 IND Accepted by CDE, Marking China’s First Masked PD-1/IL-2 Fusion Protein to Enter Clinical Trials

Bulletin Express
·
Jul 08

Shandong Boan Says China CDE Accepts IND Filing for Ba1203 Masked Anti-pd-1/il-2 Fusion Protein

Reuters
·
Jul 08

Shandong Boan Biotechnology Co - Cde Accepts Ind Application for Ba1203 Targeting Pd-1 and Il-2

THOMSON REUTERS
·
Jul 08

Shandong Boan Biotechnology - Acceptance from China's Cde of Nmpa

THOMSON REUTERS
·
Jul 08

Shandong Boan Biotechnology Gets Trial Nod for Lung Cancer Drug in China

MT Newswires Live
·
Jul 02

Boan Biotech Secures CDE Approval to Advance BA1106 + BA1104 Combo into Phase II Trial for Driver-Gene-Negative NSCLC

Bulletin Express
·
Jul 02

Shandong Boan Biotechnology Co - Cde Approves Phase Ii Trial of Anti-cd25 Antibody with Pd-1 Inhibitor for Nsclc

THOMSON REUTERS
·
Jul 02

Shandong Boan Biotech shareholders adopt restricted share unit incentive scheme at AGM

Reuters
·
Jun 22

Boan Biotechnology Licenses Diabetes Drug Biosimilar in US

MT Newswires Live
·
Jun 12

BOAN BIOTECH Grants U.S. Rights for BA5101, the First Trulicity® Biosimilar, in Licensing Agreement

Bulletin Express
·
Jun 11

BOAN BIOTECH Secures US Licensing Agreement for Dulaglutide Injection

Stock News
·
Jun 11

BRIEF-Shandong Boan Biotechnology Announces Licensing Of Dulaglutide Injection In US

Reuters
·
Jun 11

Shandong Boan Biotech licenses U.S. rights to dulaglutide biosimilar BA5101 to partner

Reuters
·
Jun 11

Shandong Boan Biotechnology Co Ltd - Licensing of Dulaglutide Injection in U.S.

THOMSON REUTERS
·
Jun 11

Boan Biotech: No Share Capital Changes in May; Public Float Remains Above 18.14% Waiver Threshold

Bulletin Express
·
Jun 03

BOAN BIOTECH Submits US Applications for Two Denosumab Biosimilars

Stock News
·
May 29

Shandong Boan Bio submits US FDA BLA for two denosumab biosimilars

Reuters
·
May 29

Shandong Boan Biotechnology Co Ltd - Bla Submission for Two Denosumab Biosimilars in U.S. to FDA

THOMSON REUTERS
·
May 29

Shandong Boan Biotechnology Co Ltd - Ba6101 Obtained Marketing Approved in Bolivia

THOMSON REUTERS
·
May 29